SCHEMBL14985669

SCHEMBL14985669

Cc1ccc2c(c1)c(=O)c1ccc(C(C)C)cc1n2C

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.43
RAB9A P51151 3/20 0.41
KDM4E B2RXH2 2/20 0.41
MAPT P10636 2/20 0.41
APAF1 O14727 1/20 0.41
PKM P14618 1/20 0.41
IDO1 P14902 1/20 0.41
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
MCL1 Q07820 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
L3MBTL1 Q9Y468 5/20 0.40
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
NPC1 O15118 2/20 0.40
TLR9 Q9NR96 1/20 0.40
CSNK2A2 P19784 1/20 0.39
CSNK2B P67870 1/20 0.39
CSNK2A1 P68400 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9980158 0.94 ATM (0.43) ATMRAB9AKDM4EMAPTAPAF1
SCHEMBL2705512 0.91 ATM (0.47) ATMRAB9AL3MBTL1MEN1KMT2A
SCHEMBL25752331 0.88 ATM (0.46) ATMRAB9AL3MBTL1MEN1KMT2A
SCHEMBL2756511 0.86 ATM (0.51) ATMRAB9AKDM4EMAPTAPAF1
SCHEMBL24667912 0.82 BCHE (0.45) RAB9AKDM4EMAPTAPAF1PKM
SCHEMBL13412890 0.82 KDM4E (0.49) ATMRAB9AKDM4EMAPTAPAF1
SCHEMBL30858723 0.82 KDM4E (0.51) ATMRAB9AKDM4EMAPTAPAF1
SCHEMBL26506582 0.82 KDM4E (0.51) ATMRAB9AKDM4EMAPTAPAF1
SCHEMBL20055039 0.82 RORA (0.41) ATMRAB9APKML3MBTL1MEN1
SCHEMBL8091816 0.80 NPC1 (0.56) ATMRAB9AKDM4EMAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9511056-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2016-12-06 US disclosed
US-8841278-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2014-09-23 US disclosed
US-20140249074-A1 ANTIVIRAL COMPOUNDS GILEAD PHARMASSET LLC (US) 2014-09-04 US disclosed
US-8822430-B2 Antiviral compounds GILEAD PHARMASSET LLC (US) 2014-09-02 US disclosed
US-8575118-B2 Antiviral compounds GILEAD SCIENCES, INC. (US) 2013-11-05 US disclosed
US-20130137877-A1 ANTIVIRAL COMPOUNDS GILEAD SCIENCES, INC. (US) 2013-05-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130137877-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ATM 4174/4885RAB9A 1694/4885KDM4E 2496/4885
US-20140249074-A1 ANTIVIRAL COMPOUNDS MAVS, EIF2AK2, ZC3HAV1 ATM 4174/4885RAB9A 1694/4885KDM4E 2496/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.